In Depth 18 Sep 2024 Two targets, one solution: The rise of bispecific antibodies Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape looks like. September 18, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Sep 2024 Estonia: Seven biotech companies to reckon with Explore Estonia’s biotech scene with 7 pioneering companies across Tallinn, Tartu, and beyond, fueled by top science parks and universities. September 17, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective development. September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2024 Vironexis’ AAV vector approach: The next frontier in cancer immunology? Delve into Vironexis’ launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform. September 16, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2024 Long non-coding RNAs: what’s behind the growing “dark genome” buzz? Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front. September 10, 2024 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 6 Sep 2024The power of tumor infiltrating lymphocytes to fight melanoma Listen to our conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline. September 6, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 4 Sep 2024 2024: a year of breakthroughs for endometrial cancer? New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs. September 4, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 3 Sep 2024 The crucial role of GS-CHO innovation in biopharmaceutical progress Learn how GS-CHO systems are advancing to improve yields and quality in biomanufacturing, meeting the rising need for effective therapeutic proteins. September 3, 2024 - 8 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2024 CAR-T drugs and parkinsonism: a cause for concern? CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt. August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 13 Aug 2024 Biologics vs. drugs: What does Ipsen’s lost case against the FDA mean for the industry? Ipsen has lost a court case against U.S. regulators to have its blockbuster cancer medication Somatuline Depot regarded as a biologic instead of a drug. August 13, 2024 - 4 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 23 Jul 2024 First AKT-targeting drug capivasertib to hit the market, could it open the door for more? As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out! July 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email